Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605370 · ClinicalTrials.gov registry record · Phase 4
Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01605370: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT01605370 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01605370, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if a drug called nebivolol can reverse inappropriate left ventricular mass (LVM) when compared to the standard of care drug metoprolol.
Interventions
- DRUG Nebivolol
- DRUG Metoprolol succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01605370
The ClinicalTrials.gov registry entry for NCT01605370 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nebivolol is the first listed.
NCT01605370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01605370 about?
NCT01605370 is a clinical study titled "Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?". The purpose of this study is to evaluate if a drug called nebivolol can reverse inappropriate left ventricular mass (LVM) when compared to the standard of care drug metoprolol.
What is the current status of trial NCT01605370?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2012-06. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01605370?
The interventions under investigation include: Nebivolol (DRUG), Metoprolol succinate (DRUG).
Who is sponsoring clinical trial NCT01605370?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.